The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 4 May 2017 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the annual general meeting – on a directed share issue of no more than 496,760 redeemable- and convertible class C shares.
The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on one or several occasions until the annual general meeting in 2018 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).
The board of directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 19 July – 22 September 2017.
The company currently holds 1,265,801 own common shares and 1,621,178 own class C shares. Subsequently to the effected repurchase of class C shares above, the number of own class C shares will amount to 2,117,938.
The class C shares will, following the repurchase, be converted to common shares in the number that is required to ensure delivery under the incentive programme.
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
For more information please contact
|Media relations||Investor relations|
|Linda Holmström, Senior Communications Manager||Jörgen Winroth, Vice President, Head of Investor Relations|
|+46 70 873 40 95||+1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
This information is information that Swedish Orphan Biovitrum AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:15 CET on 19 July 2017.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com